Prevalencia de anticuerpos anti HLA y/o HNA en muestras de donantes de sangre: una revisión sistemática
ilustraciones, diagramas
- Autores:
-
Angel Peña, Verónica
- Tipo de recurso:
- Fecha de publicación:
- 2024
- Institución:
- Universidad Nacional de Colombia
- Repositorio:
- Universidad Nacional de Colombia
- Idioma:
- spa
- OAI Identifier:
- oai:repositorio.unal.edu.co:unal/86647
- Palabra clave:
- 610 - Medicina y salud::612 - Fisiología humana
Anticuerpos
Lesión Pulmonar Aguda Postransfusional/inmunología
Donantes de Sangre
Antibodies
Transfusion-Related Acute Lung Injury/inmunology
Blood Donors
Revisión sistemática
Anticuerpos
Antígeno leucocitario humano
Antígeno plaquetario humano
Lesión pulmonar aguda relacionada con transfusión (TRALI)
Systematic review
Antibodies
Human leukocyte antigen
Human platelet antigen
Transfusion-related acute lung injury (TRALI)
- Rights
- openAccess
- License
- Atribución-NoComercial 4.0 Internacional
id |
UNACIONAL2_d111f9352bedbc2614fb2fe1aaeb12d5 |
---|---|
oai_identifier_str |
oai:repositorio.unal.edu.co:unal/86647 |
network_acronym_str |
UNACIONAL2 |
network_name_str |
Universidad Nacional de Colombia |
repository_id_str |
|
dc.title.spa.fl_str_mv |
Prevalencia de anticuerpos anti HLA y/o HNA en muestras de donantes de sangre: una revisión sistemática |
dc.title.translated.eng.fl_str_mv |
Prevalence of anti HLA and/or HNA antibodies in blood donor samples: a systematic review |
title |
Prevalencia de anticuerpos anti HLA y/o HNA en muestras de donantes de sangre: una revisión sistemática |
spellingShingle |
Prevalencia de anticuerpos anti HLA y/o HNA en muestras de donantes de sangre: una revisión sistemática 610 - Medicina y salud::612 - Fisiología humana Anticuerpos Lesión Pulmonar Aguda Postransfusional/inmunología Donantes de Sangre Antibodies Transfusion-Related Acute Lung Injury/inmunology Blood Donors Revisión sistemática Anticuerpos Antígeno leucocitario humano Antígeno plaquetario humano Lesión pulmonar aguda relacionada con transfusión (TRALI) Systematic review Antibodies Human leukocyte antigen Human platelet antigen Transfusion-related acute lung injury (TRALI) |
title_short |
Prevalencia de anticuerpos anti HLA y/o HNA en muestras de donantes de sangre: una revisión sistemática |
title_full |
Prevalencia de anticuerpos anti HLA y/o HNA en muestras de donantes de sangre: una revisión sistemática |
title_fullStr |
Prevalencia de anticuerpos anti HLA y/o HNA en muestras de donantes de sangre: una revisión sistemática |
title_full_unstemmed |
Prevalencia de anticuerpos anti HLA y/o HNA en muestras de donantes de sangre: una revisión sistemática |
title_sort |
Prevalencia de anticuerpos anti HLA y/o HNA en muestras de donantes de sangre: una revisión sistemática |
dc.creator.fl_str_mv |
Angel Peña, Verónica |
dc.contributor.advisor.spa.fl_str_mv |
Camacho Rodriguez, Bernado Armando Vallejo Ortega, María Teresa Henao Riveros, Sandra Consuelo |
dc.contributor.author.spa.fl_str_mv |
Angel Peña, Verónica |
dc.subject.ddc.spa.fl_str_mv |
610 - Medicina y salud::612 - Fisiología humana |
topic |
610 - Medicina y salud::612 - Fisiología humana Anticuerpos Lesión Pulmonar Aguda Postransfusional/inmunología Donantes de Sangre Antibodies Transfusion-Related Acute Lung Injury/inmunology Blood Donors Revisión sistemática Anticuerpos Antígeno leucocitario humano Antígeno plaquetario humano Lesión pulmonar aguda relacionada con transfusión (TRALI) Systematic review Antibodies Human leukocyte antigen Human platelet antigen Transfusion-related acute lung injury (TRALI) |
dc.subject.decs.spa.fl_str_mv |
Anticuerpos Lesión Pulmonar Aguda Postransfusional/inmunología Donantes de Sangre |
dc.subject.decs.eng.fl_str_mv |
Antibodies Transfusion-Related Acute Lung Injury/inmunology Blood Donors |
dc.subject.proposal.spa.fl_str_mv |
Revisión sistemática Anticuerpos Antígeno leucocitario humano Antígeno plaquetario humano Lesión pulmonar aguda relacionada con transfusión (TRALI) |
dc.subject.proposal.eng.fl_str_mv |
Systematic review Antibodies Human leukocyte antigen Human platelet antigen Transfusion-related acute lung injury (TRALI) |
description |
ilustraciones, diagramas |
publishDate |
2024 |
dc.date.accessioned.none.fl_str_mv |
2024-07-29T20:18:06Z |
dc.date.available.none.fl_str_mv |
2024-07-29T20:18:06Z |
dc.date.issued.none.fl_str_mv |
2024-01 |
dc.type.spa.fl_str_mv |
Trabajo de grado - Maestría |
dc.type.driver.spa.fl_str_mv |
info:eu-repo/semantics/masterThesis |
dc.type.version.spa.fl_str_mv |
info:eu-repo/semantics/acceptedVersion |
dc.type.content.spa.fl_str_mv |
Text |
dc.type.redcol.spa.fl_str_mv |
http://purl.org/redcol/resource_type/TM |
status_str |
acceptedVersion |
dc.identifier.uri.none.fl_str_mv |
https://repositorio.unal.edu.co/handle/unal/86647 |
dc.identifier.instname.spa.fl_str_mv |
Universidad Nacional de Colombia |
dc.identifier.reponame.spa.fl_str_mv |
Repositorio Institucional Universidad Nacional de Colombia |
dc.identifier.repourl.spa.fl_str_mv |
https://repositorio.unal.edu.co/ |
url |
https://repositorio.unal.edu.co/handle/unal/86647 https://repositorio.unal.edu.co/ |
identifier_str_mv |
Universidad Nacional de Colombia Repositorio Institucional Universidad Nacional de Colombia |
dc.language.iso.spa.fl_str_mv |
spa |
language |
spa |
dc.relation.indexed.spa.fl_str_mv |
Bireme |
dc.relation.references.spa.fl_str_mv |
Tung JP, Chiaretti S, Dean MM, Sultana AJ, Reade MC, Fung YL. Transfusion-related acute lung injury (TRALI): Potential pathways of development, strategies for prevention and treatment, and future research directions. Blood Rev. 2022;53:100926 Barnard RD. Indiscriminate transfusion: a critique of case reports illustrating hypersensitivity reactions. N Y State J Med. 1951;51(20):2399-402 Popovsky MA, Abel MD, Moore SB. Transfusion-related acute lung injury associated with passive transfer of antileukocyte antibodies. Am Rev Respir Dis. 1983;128(1):185-9 Popovsky MA, Moore SB. Diagnostic and pathogenetic considerations in transfusion-related acute lung injury. Transfusion. 1985;25(6):573-7 Kleinman S, Caulfield T, Chan P, Davenport R, McFarland J, McPhedran S, et al. Toward an understanding of transfusion-related acute lung injury: statement of a consensus panel. Transfusion. 2004;44(12):1774-89 Vlaar APJ, Toy P, Fung M, Looney MR, Juffermans NP, Bux J, et al. A consensus redefinition of transfusion-related acute lung injury. Transfusion. 2019;59(7):2465-76 Otrock ZK, Liu C, Grossman BJ. Transfusion-related acute lung injury risk mitigation: an update. Vox Sang. 2017;112(8):694-703 Toy P, Kleinman SH, Looney MR. Proposed revised nomenclature for transfusion-related acute lung injury. Transfusion. 2017;57(3):709-13 Sweeney RM, McAuley DF. Acute respiratory distress syndrome. Lancet. 2016;388(10058):2416-30 Silliman CC, Ambruso DR, Boshkov LK. Transfusion-related acute lung injury. Blood. 2005;105(6):2266-73 Chapman CE, Stainsby D, Jones H, Love E, Massey E, Win N, et al. Ten years of hemovigilance reports of transfusion-related acute lung injury in the United Kingdom and the impact of preferential use of male donor plasma. Transfusion. 2009;49(3):440-52 Andreu G, Boudjedir K, Muller JY, Pouchol E, Ozier Y, Fevre G, et al. Analysis of Transfusion-Related Acute Lung Injury and Possible Transfusion-Related Acute Lung Injury Reported to the French Hemovigilance Network From 2007 to 2013. Transfus Med Rev. 2018;32(1):16-27 Kopko PM, Popovsky MA, MacKenzie MR, Paglieroni TG, Muto KN, Holland PV. HLA class II antibodies in transfusion-related acute lung injury. Transfusion. 2001;41(10):1244-8 Silliman CC, Voelkel NF, Allard JD, Elzi DJ, Tuder RM, Johnson JL, et al. Plasma and lipids from stored packed red blood cells cause acute lung injury in an animal model. J Clin Invest. 1998;101(7):1458-67 Peters AL, van Hezel ME, Juffermans NP, Vlaar AP. Pathogenesis of non-antibody mediated transfusion-related acute lung injury from bench to bedside. Blood Rev. 2015;29(1):51-61 Vlaar AP, Juffermans NP. Transfusion-related acute lung injury: a clinical review. Lancet. 2013;382(9896):984-94 Toy P, Gajic O, Bacchetti P, Looney MR, Gropper MA, Hubmayr R, et al. Transfusion-related acute lung injury: incidence and risk factors. Blood. 2012;119(7):1757-67 Wyman TH, Bjornsen AJ, Elzi DJ, Smith CW, England KM, Kelher M, et al. A two-insult in vitro model of PMN-mediated pulmonary endothelial damage: requirements for adherence and chemokine release. Am J Physiol Cell Physiol. 2002;283(6):C1592-603 Vlaar AP, Kuipers MT, Hofstra JJ, Wolthuis EK, Wieland CW, Roelofs JJ, et al. Mechanical ventilation and the titer of antibodies as risk factors for the development of transfusion-related lung injury. Crit Care Res Pract. 2012;2012:720950 Rana R, Fernández-Pérez ER, Khan SA, Rana S, Winters JL, Lesnick TG, et al. Transfusion-related acute lung injury and pulmonary edema in critically ill patients: a retrospective study. Transfusion. 2006;46(9):1478-83 Gajic O, Rana R, Winters JL, Yilmaz M, Mendez JL, Rickman OB, et al. Transfusion-related acute lung injury in the critically ill: prospective nested case-control study. Am J Respir Crit Care Med. 2007;176(9):886-91 Vlaar AP, Binnekade JM, Prins D, van Stein D, Hofstra JJ, Schultz MJ, et al. Risk factors and outcome of transfusion-related acute lung injury in the critically ill: a nested case-control study. Crit Care Med. 2010;38(3):771-8 Peters AL, Van Stein D, Vlaar AP. Antibody-mediated transfusion-related acute lung injury; from discovery to prevention. Br J Haematol. 2015;170(5):597-614 Morsing KSH, Peters AL, van Buul JD, Vlaar APJ. The role of endothelium in the onset of antibody-mediated TRALI. Blood Rev. 2018;32(1):1-7 Looney MR, Nguyen JX, Hu Y, Van Ziffle JA, Lowell CA, Matthay MA. Platelet depletion and aspirin treatment protect mice in a two-event model of transfusion-related acute lung injury. J Clin Invest. 2009;119(11):3450-61 Kapur R, Kim M, Aslam R, McVey MJ, Tabuchi A, Luo A, et al. T regulatory cells and dendritic cells protect against transfusion-related acute lung injury via IL-10. Blood. 2017;129(18):2557-69 Looney MR, Su X, Van Ziffle JA, Lowell CA, Matthay MA. Neutrophils and their Fc gamma receptors are essential in a mouse model of transfusion-related acute lung injury. J Clin Invest. 2006;116(6):1615-23 Kelher MR, Banerjee A, Gamboni F, Anderson C, Silliman CC. Antibodies to major histocompatibility complex class II antigens directly prime neutrophils and cause acute lung injury in a two-event in vivo rat model. Transfusion. 2016;56(12):3004-11 Thomas GM, Carbo C, Curtis BR, Martinod K, Mazo IB, Schatzberg D, et al. Extracellular DNA traps are associated with the pathogenesis of TRALI in humans and mice. Blood. 2012;119(26):6335-43 Bux J, Sachs UJ. The pathogenesis of transfusion-related acute lung injury (TRALI). Br J Haematol. 2007;136(6):788-99 Bux J. Antibody-mediated (immune) transfusion-related acute lung injury. Vox Sang. 2011;100(1):122-8 Stroncek DF, Fadeyi E, Adams S. Leukocyte antigen and antibody detection assays: tools for assessing and preventing pulmonary transfusion reactions. Transfus Med Rev. 2007;21(4):273-86 Delbos F, Cesbron A. [Caracterization of HLA allo-immunization and clinical impact in transfusion and organ transplantation]. Transfus Clin Biol. 2017;24(3):131-7 Morsing KSH, Peters AL, van Buul JD, Vlaar APJ. The role of endothelium in the onset of antibody-mediated TRALI. Blood Reviews. 2018;32(1):1-7 Sachs UJ, Wasel W, Bayat B, Bohle RM, Hattar K, Berghöfer H, et al. Mechanism of transfusion-related acute lung injury induced by HLA class II antibodies. Blood. 2011;117(2):669-77 Seeger W, Schneider U, Kreusler B, von Witzleben E, Walmrath D, Grimminger F, et al. Reproduction of transfusion-related acute lung injury in an ex vivo lung model. Blood. 1990;76(7):1438-44 Martínez Álvarez JC. [Antibodies, human leukocyte antigens, and biomodulators in transfusion-related acute adverse effects]. Gac Med Mex. 2013;149(1):81-8 Browne T, Dearman RJ, Poles A. Human neutrophil antigens: Nature, clinical significance and detection. Int J Immunogenet. 2021;48(2):145-56 Moritz E, Norcia AM, Cardone JD, Kuwano ST, Chiba AK, Yamamoto M, et al. Human neutrophil alloantigens systems. An Acad Bras Cienc. 2009;81(3):559-69 Flesch BK, Reil A. Molecular Genetics of the Human Neutrophil Antigens. Transfus Med Hemother. 2018;45(5):300-9 AABB. Association Bulletin #14-02. 1402. EEUU2014. p. 14 Association Bulletin #14-02, (2014) Maria B, Michel G. Informe de actividad transfusional, Colombia 2022. 2023 Peñuela O, Beltrán M, Rebollo S, Bermúdez M. Manual de hemovigilancia. Bogotá, Colombia2010 Michel G, Andrea H, María B. CASO 3-2021: NOTIFICACIÓN DE MORTALIDAD SECUNDARIA A REACCIÓN ADVERSA A LA TRANSFUSIÓN POR ADMINISTRACIÓN DE HEMOCOMPONENTE ABO INCOMPATIBLE. Bogotá2022 Decreto 1571 de 1993, (1993) Cross AR. What is a Blood Bank? https://www.redcrossblood.org/local-homepage/news/article/blood-banks-defined.html [Available from: https://www.redcrossblood.org/local-homepage/news/article/blood-banks-defined.html Hematology ASo. Blood Banking and Donation https://www.hematology.org/education/patients/blood-basics/blood-banking-and-donation2021 [Available from: https://www.hematology.org/education/patients/blood-basics/blood-banking-and-donation Al MPe. Quality asssessment tool for cross sectional studies: Newcastle-Otawa Scale. 2016 Lipsey M, Wilson D. Practical Meta-Analysis <p class="EndNoteBibliography" style="margin-top:0cm;margin-right:0cm;margin-bottom: 0cm;margin-left:36.0pt;margin-bottom:.0001pt;text-indent:-36.0pt">. 1 ed. California2001 Deeks J, Higgins J, Altman D. Analysing data and undertaking meta-analyses. In: Higgins J, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions (Version 510 ed). London: The Cochrane Collaboration; 2011 Boulton-Jones R, Norris A, O'Sullivan A, Comrie A, Forgan M, Rawlinson PS, et al. The impact of screening a platelet donor panel for human leucocyte antigen antibodies to reduce the risk of transfusion-related acute lung injury. Transfus Med. 2003;13(3):169-70 Bray RA, Harris SB, Josephson CD, Hillyer CD, Gebel HM. Unappreciated risk factors for transplant patients: HLA antibodies in blood components. Hum Immunol. 2004;65(3):240-4 Carrick DM, Johnson B, Kleinman SH, Vorhaben R, Chance SC, Lee JH, et al. Agreement among HLA antibody detection assays is higher in ever-pregnant donors and improved using a consensus cutoff. Transfusion. 2011;51(5):1105-16 De Clippel D, Baeten M, Torfs A, Emonds MP, Feys HB, Compernolle V, et al. Screening for HLA antibodies in plateletpheresis donors with a history of transfusion or pregnancy. Transfusion. 2014;54(12):3036-42 Densmore TL, Goodnough LT, Ali S, Dynis M, Chaplin H. Prevalence of HLA sensitization in female apheresis donors. Transfusion. 1999;39(1):103-6 Dunbar NM, Yazer MH, Bravo MD, Kamel HT, Gorlin J, Norris PJ, et al. An association between ABO group and HLA antibody detection. Transfusion. 2017;57(2):313-8 Fadeyi E, Adams S, Peterson B, Hackett J, Byrne P, Klein HG, et al. Analysis of a high-throughput HLA antibody screening assay for use with platelet donors. Transfusion. 2008;48(6):1174-9 Gottschall JL, Triulzi DJ, Curtis B, Kakaiya RM, Busch MP, Norris PJ, et al. The frequency and specificity of human neutrophil antigen antibodies in a blood donor population. Transfusion. 2011;51(4):820-7 Hernández H, Romero A. FRECUENCIA DE ANTICUERPOS ANTI - HLA DE CLASE I EN DODNATES MULTIPARAS DE PLAQUETAS POR AFERESIS Y SANGRE TOTAL DEL BANCO NACIONAL DE SANGRE DE LA CRUZ ROJA COLOMBIANA: Pontificia Universidad Javeriana; 2011 Insunza A, Romon I, Gonzalez-Ponte ML, Hoyos A, Pastor JM, Iriondo A, et al. Implementation of a strategy to prevent TRALI in a regional blood centre. Transfus Med. 2004;14(2):157-64 Kakaiya RM, Triulzi DJ, Wright DJ, Steele WR, Kleinman SH, Busch MP, et al. Prevalence of HLA antibodies in remotely transfused or alloexposed volunteer blood donors. Transfusion. 2010;50(6):1328-34 Lucas G, Win N, Calvert A, Green A, Griffin E, Bendukidze N, et al. Reducing the incidence of TRALI in the UK: the results of screening for donor leucocyte antibodies and the development of national guidelines. Vox Sang. 2012;103(1):10-7 Nguyen XD, Dengler T, Schulz-Linkholt M, Klüter H. A novel tool for high-throughput screening of granulocyte-specific antibodies using the automated flow cytometric granulocyte immunofluorescence test (Flow-GIFT). ScientificWorldJournal. 2011;11:302-9 Nguyen XD, Schulze TJ, Bugert P, Lauber-Härtl S, Schulz-Linkholt M, González-Schulze K, et al. Granulocyte antibodies in male blood donors: can they trigger transfusion-related acute lung injury? Transfusion. 2018;58(8):1894-901 Nowosiad-Magda M, Myślak M, Roszkowska P, Borowiec-Chłopek Z, Krasnodębska-Szponder B, Kłosińska E, et al. Anti-human leukocyte antigen antibodies are present in blood of blood donors: is therapy with blood preparations safe for graft recipients? Transplant Proc. 2014;46(8):2565-71 Porretti L, Cattaneo A, Coluccio E, Mantione E, Colombo F, Mariani M, et al. Implementation and outcomes of a transfusion-related acute lung injury surveillance programme and study of HLA/HNA alloimmunisation in blood donors. Blood Transfus. 2012;10(3):351-9 Powers A, Stowell CP, Dzik WH, Saidman SL, Lee H, Makar RS. Testing only donors with a prior history of pregnancy or transfusion is a logical and cost-effective transfusion-related acute lung injury prevention strategy. Transfusion. 2008;48(12):2549-58 Priyadarsini AJ, Dhawan HK, Sharma RR, Saikia B, Minz RW. Prevalance of Anti-HLA antibodies in parous female blood donors: A pilot study from tertiary care hospital of North India. Asian J Transfus Sci. 2021;15(1):16-20 Quillen K, Medrano C, Adams S, Peterson B, Hackett J, Leitman SF, et al. Screening plateletpheresis donors for HLA antibodies on two high-throughput platforms and correlation with recipient outcome. Transfusion. 2011;51(3):504-10 Reil A, Keller-Stanislawski B, Günay S, Bux J. Specificities of leucocyte alloantibodies in transfusion-related acute lung injury and results of leucocyte antibody screening of blood donors. Vox Sang. 2008;95(4):313-7 Sachs UJ, Link E, Hofmann C, Wasel W, Bein G. Screening of multiparous women to avoid transfusion-related acute lung injury: a single centre experience. Transfus Med. 2008;18(6):348-54 Schönbacher M, Aichinger N, Weidner L, Jungbauer C, Grabmer C, Schuha B, et al. Leukocyte-Reactive Antibodies in Female Blood Donors: The Austrian Experience. Transfus Med Hemother. 2021;48(2):99-108 Sigle JP, Thierbach J, Infanti L, Muriset M, Hunziker G, Chassot K, et al. Anti-leucocyte antibodies in platelet apheresis donors with and without prior immunizing events: implications for TRALI prevention. Vox Sang. 2013;105(3):244-52 Simtong P, Sudwilai Y, Cheunta S, Leelayuwat C, Romphruk AV. Prevalence of leucocyte antibodies in non-transfused male and female platelet apheresis donors. Transfus Med. 2021;31(3):186-92 Triulzi DJ, Kleinman S, Kakaiya RM, Busch MP, Norris PJ, Steele WR, et al. The effect of previous pregnancy and transfusion on HLA alloimmunization in blood donors: implications for a transfusion-related acute lung injury risk reduction strategy. Transfusion. 2009;49(9):1825-35 Xia W, Ye X, Xu X, Chen D, Deng J, Chen Y, et al. The prevalence of leucocyte alloantibodies in blood donors from South China. Transfus Med. 2015;25(6):385-92 Endres RO, Kleinman SH, Carrick DM, Steele WR, Wright DJ, Norris PJ, et al. Identification of specificities of antibodies against human leukocyte antigens in blood donors. Transfusion. 2010;50(8):1749-60 Maślanka K, Michur H, Zupańska B, Uhrynowska M, Nowak J. Leucocyte antibodies in blood donors and a look back on recipients of their blood components. Vox Sang. 2007;92(3):247-9 Middelburg RA, Porcelijn L, Lardy N, Briët E, Vrielink H. Prevalence of leucocyte antibodies in the Dutch donor population. Vox Sang. 2011;100(3):327-35 Bray RA, Nickerson PW, Kerman RH, Gebel HM. Evolution of HLA antibody detection: technology emulating biology. Immunol Res. 2004;29(1-3):41-54 Nakamura J, Nakajima F, Kamada H, Tadokoro K, Nagai T, Satake M. Males without apparent alloimmunization could have HLA antibodies that recognize target HLA specificities expressed on cells. HLA. 2017;89(5):285-92 Morales-Buenrostro LE, Terasaki PI, Marino-Vázquez LA, Lee JH, El-Awar N, Alberú J. "Natural" human leukocyte antigen antibodies found in nonalloimmunized healthy males. Transplantation. 2008;86(8):1111-5 El-Awar N. HLA epitopes - Empirically defined as conformational amino acids sequences of the HLA antigen and are likely to be part of the binding sites of anti-HLA antibodies. Hum Immunol. 2022;83(3):204-18 |
dc.rights.coar.fl_str_mv |
http://purl.org/coar/access_right/c_abf2 |
dc.rights.license.spa.fl_str_mv |
Atribución-NoComercial 4.0 Internacional |
dc.rights.uri.spa.fl_str_mv |
http://creativecommons.org/licenses/by-nc/4.0/ |
dc.rights.accessrights.spa.fl_str_mv |
info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Atribución-NoComercial 4.0 Internacional http://creativecommons.org/licenses/by-nc/4.0/ http://purl.org/coar/access_right/c_abf2 |
eu_rights_str_mv |
openAccess |
dc.format.extent.spa.fl_str_mv |
xiii, 75 páginas |
dc.format.mimetype.spa.fl_str_mv |
application/pdf |
dc.publisher.spa.fl_str_mv |
Universidad Nacional de Colombia |
dc.publisher.program.spa.fl_str_mv |
Bogotá - Medicina - Maestría en Inmunología |
dc.publisher.faculty.spa.fl_str_mv |
Facultad de Medicina |
dc.publisher.place.spa.fl_str_mv |
Bogotá, Colombia |
dc.publisher.branch.spa.fl_str_mv |
Universidad Nacional de Colombia - Sede Bogotá |
institution |
Universidad Nacional de Colombia |
bitstream.url.fl_str_mv |
https://repositorio.unal.edu.co/bitstream/unal/86647/3/license.txt https://repositorio.unal.edu.co/bitstream/unal/86647/4/53160608.2024.pdf https://repositorio.unal.edu.co/bitstream/unal/86647/5/53160608.2024.pdf.jpg |
bitstream.checksum.fl_str_mv |
eb34b1cf90b7e1103fc9dfd26be24b4a 6ea78d1761e2627fc5a6baf776cfacfd 03931df280ef8c1d08916bbb12af4ad4 |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 |
repository.name.fl_str_mv |
Repositorio Institucional Universidad Nacional de Colombia |
repository.mail.fl_str_mv |
repositorio_nal@unal.edu.co |
_version_ |
1814089746770558976 |
spelling |
Atribución-NoComercial 4.0 Internacionalhttp://creativecommons.org/licenses/by-nc/4.0/info:eu-repo/semantics/openAccesshttp://purl.org/coar/access_right/c_abf2Camacho Rodriguez, Bernado Armando88e2b81e47b2899669514e6806335352600Vallejo Ortega, María Teresa640cb854bc6f2b1f5781946cd62f099c600Henao Riveros, Sandra Consuelo37ae82bfbf54523207ffb0a58ab27e3d600Angel Peña, Verónica589d87aec5d6546f87e57a484a415d7e2024-07-29T20:18:06Z2024-07-29T20:18:06Z2024-01https://repositorio.unal.edu.co/handle/unal/86647Universidad Nacional de ColombiaRepositorio Institucional Universidad Nacional de Colombiahttps://repositorio.unal.edu.co/ilustraciones, diagramasIntroducción: Los anticuerpos anti-HLA y anti-HNA se encuentran dirigidos contra antígenos que se encuentran en los leucocitos y otras células (los antígenos HNA se encuentran sobre los neutrófilos, y los antígenos HLA sobre la mayoría de células nucleadas). Se han descrito dos sistemas de antígenos leucocitarios: el sistema HLA y el sistema HNA; si bien son bastante diferentes, están asociados por causar TRALI, una condición asociada a la transfusión de componentes sanguíneos que contienen estos anticuerpos, y que puede llegar a comprometer la vida del paciente. Se realizó una revisión sistemática para establecer la frecuencia de estos anticuerpos en donantes de sangre. Objetivo: Determinar la prevalencia de prueba positiva para anticuerpos anti-HLA y anti-HNA en muestras de donantes de sangre Métodos de búsqueda: Se realizó una búsqueda sistemática en las bases de datos electrónicas MEDLINE, EMBASE y LILACS para detectar estudios observacionales o experimentales que hayan medido la prevalencia de anticuerpos anti-HLA, anti-HNA o ambos en muestras de donantes de sangre, ensayos clínicos que compararon la capacidad de pruebas de detección de los anticuerpos y estudios de pruebas diagnósticas que evaluaron la exactitud de las pruebas usadas. Luego de la extracción y calificación por dos investigadores, se evaluó la heterogeneidad y se generaron estimadores de resumen mediante metaanálisis de proporciones por método directo. Resultados principales: Como resultados de la búsqueda fueron detectadas 3340 referencias, luego del proceso de selección fueron incluidos un total de 23 estudios; de los cuales 22 hicieron detección de anticuerpos anti-HLA total y 12 hicieron detección de anticuerpos anti-HNA. Se reportaron los rangos de prevalencias para anticuerpos anti-HLA mediante síntesis textual narrativa debido a que se obtuvieron valores de I2 mayores al 70%. La prevalencia resumida de HNA total fue del 1%. Conclusiones: Existe una alta incertidumbre sobre la magnitud de la prevalencia de anticuerpos anti-HLA y anti-HNA en donantes de bancos de sangre. Podría haber una mayor prevalencia de anticuerpos en mujeres con más de una gestación, pero se requieren estudios que precisen otros factores que puedan mejorar la certeza de la prevalencia de anticuerpos en esta población y expliquen la alta heterogeneidad encontrada. Se necesitan investigaciones adicionales permitan estimar el efecto de los eventos sensibilizantes con la prevalencia de anticuerpos anti-HLA y anti-HNA en donantes de sangre. (Texto tomado de la fuente).Introduction: Anti-HLA and anti-HNA antibodies are directed against antigens found on leukocytes and other cells (HNA antigens are found on neutrophils, and HLA antigens on most nucleated cells). Two leukocyte antigen systems have been described: the HLA system and the HNA system; Although they are quite different, they are associated with causing TRALI, a condition associated with the transfusion of blood components that contain these antibodies, and which can compromise the patient's life. A systematic review was performed to establish the frequency of these antibodies in blood donors. Objective: Determine the prevalence of positive tests for anti-HLA and anti-HNA antibodies in blood donor samples. Search methods: A systematic search was performed in the electronic databases MEDLINE, EMBASE and LILACS to detect observational or experimental studies that have measured the prevalence of anti-HLA antibodies, anti-HNA antibodies or both in blood donor samples, assays clinical trials that compared the ability of antibody detection tests and diagnostic testing studies that evaluated the accuracy of the tests used. After extraction and scoring by two researchers, heterogeneity was assessed and summary estimators were generated through meta-analysis of proportions by direct method. Results: As results of the search, 3340 references were detected, after the selection process a total of 23 studies were included; of which 22 detected total anti-HLA antibodies and 12 detected anti-HNA antibodies. The prevalence ranges for anti-HLA antibodies were reported through narrative textual synthesis because I2 values greater than 70% were obtained. The summary prevalence of total HNA was 1%. Conclusions: There is high uncertainty about the magnitude of the prevalence of anti-HLA and anti-HNA antibodies in blood bank donors. There could be a higher prevalence of antibodies in women with more than one pregnancy, but studies are required that specify other factors that can improve the certainty of the prevalence of antibodies in this population and explain the high heterogeneity found. Additional research is needed to estimate the effect of sensitizing events on the prevalence of anti-HLA and anti-HNA antibodies in blood donors.MaestríaMagíster en Inmunologíaxiii, 75 páginasapplication/pdfspaUniversidad Nacional de ColombiaBogotá - Medicina - Maestría en InmunologíaFacultad de MedicinaBogotá, ColombiaUniversidad Nacional de Colombia - Sede Bogotá610 - Medicina y salud::612 - Fisiología humanaAnticuerposLesión Pulmonar Aguda Postransfusional/inmunologíaDonantes de SangreAntibodiesTransfusion-Related Acute Lung Injury/inmunologyBlood DonorsRevisión sistemáticaAnticuerposAntígeno leucocitario humanoAntígeno plaquetario humanoLesión pulmonar aguda relacionada con transfusión (TRALI)Systematic reviewAntibodiesHuman leukocyte antigenHuman platelet antigenTransfusion-related acute lung injury (TRALI)Prevalencia de anticuerpos anti HLA y/o HNA en muestras de donantes de sangre: una revisión sistemáticaPrevalence of anti HLA and/or HNA antibodies in blood donor samples: a systematic reviewTrabajo de grado - Maestríainfo:eu-repo/semantics/masterThesisinfo:eu-repo/semantics/acceptedVersionTexthttp://purl.org/redcol/resource_type/TMBiremeTung JP, Chiaretti S, Dean MM, Sultana AJ, Reade MC, Fung YL. Transfusion-related acute lung injury (TRALI): Potential pathways of development, strategies for prevention and treatment, and future research directions. Blood Rev. 2022;53:100926Barnard RD. Indiscriminate transfusion: a critique of case reports illustrating hypersensitivity reactions. N Y State J Med. 1951;51(20):2399-402Popovsky MA, Abel MD, Moore SB. Transfusion-related acute lung injury associated with passive transfer of antileukocyte antibodies. Am Rev Respir Dis. 1983;128(1):185-9Popovsky MA, Moore SB. Diagnostic and pathogenetic considerations in transfusion-related acute lung injury. Transfusion. 1985;25(6):573-7Kleinman S, Caulfield T, Chan P, Davenport R, McFarland J, McPhedran S, et al. Toward an understanding of transfusion-related acute lung injury: statement of a consensus panel. Transfusion. 2004;44(12):1774-89Vlaar APJ, Toy P, Fung M, Looney MR, Juffermans NP, Bux J, et al. A consensus redefinition of transfusion-related acute lung injury. Transfusion. 2019;59(7):2465-76Otrock ZK, Liu C, Grossman BJ. Transfusion-related acute lung injury risk mitigation: an update. Vox Sang. 2017;112(8):694-703Toy P, Kleinman SH, Looney MR. Proposed revised nomenclature for transfusion-related acute lung injury. Transfusion. 2017;57(3):709-13Sweeney RM, McAuley DF. Acute respiratory distress syndrome. Lancet. 2016;388(10058):2416-30Silliman CC, Ambruso DR, Boshkov LK. Transfusion-related acute lung injury. Blood. 2005;105(6):2266-73Chapman CE, Stainsby D, Jones H, Love E, Massey E, Win N, et al. Ten years of hemovigilance reports of transfusion-related acute lung injury in the United Kingdom and the impact of preferential use of male donor plasma. Transfusion. 2009;49(3):440-52Andreu G, Boudjedir K, Muller JY, Pouchol E, Ozier Y, Fevre G, et al. Analysis of Transfusion-Related Acute Lung Injury and Possible Transfusion-Related Acute Lung Injury Reported to the French Hemovigilance Network From 2007 to 2013. Transfus Med Rev. 2018;32(1):16-27Kopko PM, Popovsky MA, MacKenzie MR, Paglieroni TG, Muto KN, Holland PV. HLA class II antibodies in transfusion-related acute lung injury. Transfusion. 2001;41(10):1244-8Silliman CC, Voelkel NF, Allard JD, Elzi DJ, Tuder RM, Johnson JL, et al. Plasma and lipids from stored packed red blood cells cause acute lung injury in an animal model. J Clin Invest. 1998;101(7):1458-67Peters AL, van Hezel ME, Juffermans NP, Vlaar AP. Pathogenesis of non-antibody mediated transfusion-related acute lung injury from bench to bedside. Blood Rev. 2015;29(1):51-61Vlaar AP, Juffermans NP. Transfusion-related acute lung injury: a clinical review. Lancet. 2013;382(9896):984-94Toy P, Gajic O, Bacchetti P, Looney MR, Gropper MA, Hubmayr R, et al. Transfusion-related acute lung injury: incidence and risk factors. Blood. 2012;119(7):1757-67Wyman TH, Bjornsen AJ, Elzi DJ, Smith CW, England KM, Kelher M, et al. A two-insult in vitro model of PMN-mediated pulmonary endothelial damage: requirements for adherence and chemokine release. Am J Physiol Cell Physiol. 2002;283(6):C1592-603Vlaar AP, Kuipers MT, Hofstra JJ, Wolthuis EK, Wieland CW, Roelofs JJ, et al. Mechanical ventilation and the titer of antibodies as risk factors for the development of transfusion-related lung injury. Crit Care Res Pract. 2012;2012:720950Rana R, Fernández-Pérez ER, Khan SA, Rana S, Winters JL, Lesnick TG, et al. Transfusion-related acute lung injury and pulmonary edema in critically ill patients: a retrospective study. Transfusion. 2006;46(9):1478-83Gajic O, Rana R, Winters JL, Yilmaz M, Mendez JL, Rickman OB, et al. Transfusion-related acute lung injury in the critically ill: prospective nested case-control study. Am J Respir Crit Care Med. 2007;176(9):886-91Vlaar AP, Binnekade JM, Prins D, van Stein D, Hofstra JJ, Schultz MJ, et al. Risk factors and outcome of transfusion-related acute lung injury in the critically ill: a nested case-control study. Crit Care Med. 2010;38(3):771-8Peters AL, Van Stein D, Vlaar AP. Antibody-mediated transfusion-related acute lung injury; from discovery to prevention. Br J Haematol. 2015;170(5):597-614Morsing KSH, Peters AL, van Buul JD, Vlaar APJ. The role of endothelium in the onset of antibody-mediated TRALI. Blood Rev. 2018;32(1):1-7Looney MR, Nguyen JX, Hu Y, Van Ziffle JA, Lowell CA, Matthay MA. Platelet depletion and aspirin treatment protect mice in a two-event model of transfusion-related acute lung injury. J Clin Invest. 2009;119(11):3450-61Kapur R, Kim M, Aslam R, McVey MJ, Tabuchi A, Luo A, et al. T regulatory cells and dendritic cells protect against transfusion-related acute lung injury via IL-10. Blood. 2017;129(18):2557-69Looney MR, Su X, Van Ziffle JA, Lowell CA, Matthay MA. Neutrophils and their Fc gamma receptors are essential in a mouse model of transfusion-related acute lung injury. J Clin Invest. 2006;116(6):1615-23Kelher MR, Banerjee A, Gamboni F, Anderson C, Silliman CC. Antibodies to major histocompatibility complex class II antigens directly prime neutrophils and cause acute lung injury in a two-event in vivo rat model. Transfusion. 2016;56(12):3004-11Thomas GM, Carbo C, Curtis BR, Martinod K, Mazo IB, Schatzberg D, et al. Extracellular DNA traps are associated with the pathogenesis of TRALI in humans and mice. Blood. 2012;119(26):6335-43Bux J, Sachs UJ. The pathogenesis of transfusion-related acute lung injury (TRALI). Br J Haematol. 2007;136(6):788-99Bux J. Antibody-mediated (immune) transfusion-related acute lung injury. Vox Sang. 2011;100(1):122-8Stroncek DF, Fadeyi E, Adams S. Leukocyte antigen and antibody detection assays: tools for assessing and preventing pulmonary transfusion reactions. Transfus Med Rev. 2007;21(4):273-86Delbos F, Cesbron A. [Caracterization of HLA allo-immunization and clinical impact in transfusion and organ transplantation]. Transfus Clin Biol. 2017;24(3):131-7Morsing KSH, Peters AL, van Buul JD, Vlaar APJ. The role of endothelium in the onset of antibody-mediated TRALI. Blood Reviews. 2018;32(1):1-7Sachs UJ, Wasel W, Bayat B, Bohle RM, Hattar K, Berghöfer H, et al. Mechanism of transfusion-related acute lung injury induced by HLA class II antibodies. Blood. 2011;117(2):669-77Seeger W, Schneider U, Kreusler B, von Witzleben E, Walmrath D, Grimminger F, et al. Reproduction of transfusion-related acute lung injury in an ex vivo lung model. Blood. 1990;76(7):1438-44Martínez Álvarez JC. [Antibodies, human leukocyte antigens, and biomodulators in transfusion-related acute adverse effects]. Gac Med Mex. 2013;149(1):81-8Browne T, Dearman RJ, Poles A. Human neutrophil antigens: Nature, clinical significance and detection. Int J Immunogenet. 2021;48(2):145-56Moritz E, Norcia AM, Cardone JD, Kuwano ST, Chiba AK, Yamamoto M, et al. Human neutrophil alloantigens systems. An Acad Bras Cienc. 2009;81(3):559-69Flesch BK, Reil A. Molecular Genetics of the Human Neutrophil Antigens. Transfus Med Hemother. 2018;45(5):300-9AABB. Association Bulletin #14-02. 1402. EEUU2014. p. 14Association Bulletin #14-02, (2014)Maria B, Michel G. Informe de actividad transfusional, Colombia 2022. 2023Peñuela O, Beltrán M, Rebollo S, Bermúdez M. Manual de hemovigilancia. Bogotá, Colombia2010Michel G, Andrea H, María B. CASO 3-2021: NOTIFICACIÓN DE MORTALIDAD SECUNDARIA A REACCIÓN ADVERSA A LA TRANSFUSIÓN POR ADMINISTRACIÓN DE HEMOCOMPONENTE ABO INCOMPATIBLE. Bogotá2022Decreto 1571 de 1993, (1993)Cross AR. What is a Blood Bank? https://www.redcrossblood.org/local-homepage/news/article/blood-banks-defined.html [Available from: https://www.redcrossblood.org/local-homepage/news/article/blood-banks-defined.htmlHematology ASo. Blood Banking and Donation https://www.hematology.org/education/patients/blood-basics/blood-banking-and-donation2021 [Available from: https://www.hematology.org/education/patients/blood-basics/blood-banking-and-donationAl MPe. Quality asssessment tool for cross sectional studies: Newcastle-Otawa Scale. 2016Lipsey M, Wilson D. Practical Meta-Analysis <p class="EndNoteBibliography" style="margin-top:0cm;margin-right:0cm;margin-bottom: 0cm;margin-left:36.0pt;margin-bottom:.0001pt;text-indent:-36.0pt">. 1 ed. California2001Deeks J, Higgins J, Altman D. Analysing data and undertaking meta-analyses. In: Higgins J, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions (Version 510 ed). London: The Cochrane Collaboration; 2011Boulton-Jones R, Norris A, O'Sullivan A, Comrie A, Forgan M, Rawlinson PS, et al. The impact of screening a platelet donor panel for human leucocyte antigen antibodies to reduce the risk of transfusion-related acute lung injury. Transfus Med. 2003;13(3):169-70Bray RA, Harris SB, Josephson CD, Hillyer CD, Gebel HM. Unappreciated risk factors for transplant patients: HLA antibodies in blood components. Hum Immunol. 2004;65(3):240-4Carrick DM, Johnson B, Kleinman SH, Vorhaben R, Chance SC, Lee JH, et al. Agreement among HLA antibody detection assays is higher in ever-pregnant donors and improved using a consensus cutoff. Transfusion. 2011;51(5):1105-16De Clippel D, Baeten M, Torfs A, Emonds MP, Feys HB, Compernolle V, et al. Screening for HLA antibodies in plateletpheresis donors with a history of transfusion or pregnancy. Transfusion. 2014;54(12):3036-42Densmore TL, Goodnough LT, Ali S, Dynis M, Chaplin H. Prevalence of HLA sensitization in female apheresis donors. Transfusion. 1999;39(1):103-6Dunbar NM, Yazer MH, Bravo MD, Kamel HT, Gorlin J, Norris PJ, et al. An association between ABO group and HLA antibody detection. Transfusion. 2017;57(2):313-8Fadeyi E, Adams S, Peterson B, Hackett J, Byrne P, Klein HG, et al. Analysis of a high-throughput HLA antibody screening assay for use with platelet donors. Transfusion. 2008;48(6):1174-9Gottschall JL, Triulzi DJ, Curtis B, Kakaiya RM, Busch MP, Norris PJ, et al. The frequency and specificity of human neutrophil antigen antibodies in a blood donor population. Transfusion. 2011;51(4):820-7Hernández H, Romero A. FRECUENCIA DE ANTICUERPOS ANTI - HLA DE CLASE I EN DODNATES MULTIPARAS DE PLAQUETAS POR AFERESIS Y SANGRE TOTAL DEL BANCO NACIONAL DE SANGRE DE LA CRUZ ROJA COLOMBIANA: Pontificia Universidad Javeriana; 2011Insunza A, Romon I, Gonzalez-Ponte ML, Hoyos A, Pastor JM, Iriondo A, et al. Implementation of a strategy to prevent TRALI in a regional blood centre. Transfus Med. 2004;14(2):157-64Kakaiya RM, Triulzi DJ, Wright DJ, Steele WR, Kleinman SH, Busch MP, et al. Prevalence of HLA antibodies in remotely transfused or alloexposed volunteer blood donors. Transfusion. 2010;50(6):1328-34Lucas G, Win N, Calvert A, Green A, Griffin E, Bendukidze N, et al. Reducing the incidence of TRALI in the UK: the results of screening for donor leucocyte antibodies and the development of national guidelines. Vox Sang. 2012;103(1):10-7Nguyen XD, Dengler T, Schulz-Linkholt M, Klüter H. A novel tool for high-throughput screening of granulocyte-specific antibodies using the automated flow cytometric granulocyte immunofluorescence test (Flow-GIFT). ScientificWorldJournal. 2011;11:302-9Nguyen XD, Schulze TJ, Bugert P, Lauber-Härtl S, Schulz-Linkholt M, González-Schulze K, et al. Granulocyte antibodies in male blood donors: can they trigger transfusion-related acute lung injury? Transfusion. 2018;58(8):1894-901Nowosiad-Magda M, Myślak M, Roszkowska P, Borowiec-Chłopek Z, Krasnodębska-Szponder B, Kłosińska E, et al. Anti-human leukocyte antigen antibodies are present in blood of blood donors: is therapy with blood preparations safe for graft recipients? Transplant Proc. 2014;46(8):2565-71Porretti L, Cattaneo A, Coluccio E, Mantione E, Colombo F, Mariani M, et al. Implementation and outcomes of a transfusion-related acute lung injury surveillance programme and study of HLA/HNA alloimmunisation in blood donors. Blood Transfus. 2012;10(3):351-9Powers A, Stowell CP, Dzik WH, Saidman SL, Lee H, Makar RS. Testing only donors with a prior history of pregnancy or transfusion is a logical and cost-effective transfusion-related acute lung injury prevention strategy. Transfusion. 2008;48(12):2549-58Priyadarsini AJ, Dhawan HK, Sharma RR, Saikia B, Minz RW. Prevalance of Anti-HLA antibodies in parous female blood donors: A pilot study from tertiary care hospital of North India. Asian J Transfus Sci. 2021;15(1):16-20Quillen K, Medrano C, Adams S, Peterson B, Hackett J, Leitman SF, et al. Screening plateletpheresis donors for HLA antibodies on two high-throughput platforms and correlation with recipient outcome. Transfusion. 2011;51(3):504-10Reil A, Keller-Stanislawski B, Günay S, Bux J. Specificities of leucocyte alloantibodies in transfusion-related acute lung injury and results of leucocyte antibody screening of blood donors. Vox Sang. 2008;95(4):313-7Sachs UJ, Link E, Hofmann C, Wasel W, Bein G. Screening of multiparous women to avoid transfusion-related acute lung injury: a single centre experience. Transfus Med. 2008;18(6):348-54Schönbacher M, Aichinger N, Weidner L, Jungbauer C, Grabmer C, Schuha B, et al. Leukocyte-Reactive Antibodies in Female Blood Donors: The Austrian Experience. Transfus Med Hemother. 2021;48(2):99-108Sigle JP, Thierbach J, Infanti L, Muriset M, Hunziker G, Chassot K, et al. Anti-leucocyte antibodies in platelet apheresis donors with and without prior immunizing events: implications for TRALI prevention. Vox Sang. 2013;105(3):244-52Simtong P, Sudwilai Y, Cheunta S, Leelayuwat C, Romphruk AV. Prevalence of leucocyte antibodies in non-transfused male and female platelet apheresis donors. Transfus Med. 2021;31(3):186-92Triulzi DJ, Kleinman S, Kakaiya RM, Busch MP, Norris PJ, Steele WR, et al. The effect of previous pregnancy and transfusion on HLA alloimmunization in blood donors: implications for a transfusion-related acute lung injury risk reduction strategy. Transfusion. 2009;49(9):1825-35Xia W, Ye X, Xu X, Chen D, Deng J, Chen Y, et al. The prevalence of leucocyte alloantibodies in blood donors from South China. Transfus Med. 2015;25(6):385-92Endres RO, Kleinman SH, Carrick DM, Steele WR, Wright DJ, Norris PJ, et al. Identification of specificities of antibodies against human leukocyte antigens in blood donors. Transfusion. 2010;50(8):1749-60Maślanka K, Michur H, Zupańska B, Uhrynowska M, Nowak J. Leucocyte antibodies in blood donors and a look back on recipients of their blood components. Vox Sang. 2007;92(3):247-9Middelburg RA, Porcelijn L, Lardy N, Briët E, Vrielink H. Prevalence of leucocyte antibodies in the Dutch donor population. Vox Sang. 2011;100(3):327-35Bray RA, Nickerson PW, Kerman RH, Gebel HM. Evolution of HLA antibody detection: technology emulating biology. Immunol Res. 2004;29(1-3):41-54Nakamura J, Nakajima F, Kamada H, Tadokoro K, Nagai T, Satake M. Males without apparent alloimmunization could have HLA antibodies that recognize target HLA specificities expressed on cells. HLA. 2017;89(5):285-92Morales-Buenrostro LE, Terasaki PI, Marino-Vázquez LA, Lee JH, El-Awar N, Alberú J. "Natural" human leukocyte antigen antibodies found in nonalloimmunized healthy males. Transplantation. 2008;86(8):1111-5El-Awar N. HLA epitopes - Empirically defined as conformational amino acids sequences of the HLA antigen and are likely to be part of the binding sites of anti-HLA antibodies. Hum Immunol. 2022;83(3):204-18EstudiantesInvestigadoresMaestrosPúblico generalLICENSElicense.txtlicense.txttext/plain; charset=utf-85879https://repositorio.unal.edu.co/bitstream/unal/86647/3/license.txteb34b1cf90b7e1103fc9dfd26be24b4aMD53ORIGINAL53160608.2024.pdf53160608.2024.pdfTesis de Maestría en Inmunologíaapplication/pdf1488420https://repositorio.unal.edu.co/bitstream/unal/86647/4/53160608.2024.pdf6ea78d1761e2627fc5a6baf776cfacfdMD54THUMBNAIL53160608.2024.pdf.jpg53160608.2024.pdf.jpgGenerated Thumbnailimage/jpeg4756https://repositorio.unal.edu.co/bitstream/unal/86647/5/53160608.2024.pdf.jpg03931df280ef8c1d08916bbb12af4ad4MD55unal/86647oai:repositorio.unal.edu.co:unal/866472024-08-27 23:10:45.659Repositorio Institucional Universidad Nacional de Colombiarepositorio_nal@unal.edu.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 |